Observation of first-time DLBCL treatment at Charleroi hospital
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is watching how people with newly diagnosed diffuse large B cell lymphoma (a blood cancer) are treated for the first time at Grand Hôpital de Charleroi. It collects information to help doctors learn more about the disease and its care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B cell lymphoma (a type of blood cancer).
- You are being treated for this lymphoma for the first time.
- You are being treated at the Grand Hôpital de Charleroi.
- You are 18 years old or older.
- You can understand the study information and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.